Spotlight On... precisionFDA launches in hopes of accelerating personalized medicine; Mayo Clinic, Minnesota Medical partner in fecal incontinence; Siemens Healthcare exec heads to startup;

Following President Obama's call for "precision medicine," the FDA has launched precisionFDA. The initiative is an online, cloud-based portal designed to foster collaboration between multiple stakeholders in industry, academia and government. The initiative "provides a publicly accessible online portal that enables community members to conduct genome analyses for comparison against reference material, then publish the results for review," explains the Personalized Medicine Coalition, which lauded the initiative to generate knowledge for future regulatory decisions. The launch commenced with the kickoff of an initial open beta version of the portal. More from the FDA's blog | Here's reaction from the Personalized Medicine Coalition

@FierceMedDev: ICYMI yesterday: Cleveland Clinic-partnered low-cost MRI provider nabs $6.5M to kick off national expansion. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI Friday: Lab experts lash out at move to beef up regulation of lab-developed tests. Article | Follow @EmilyWFierce

> The Mayo Clinic has partnered with startup Minnesota Medical Technologies to refine, test and market the company's fecal incontinence device. More

> A 24-patient study for newly diagnosed brain metastasis for IsoRay's ($ISR) Cs-131 brachytherapy seeds found that their insertion during surgical resection helped to stabilize and improve neurocognitive function by improving control of brain tumors and avoiding whole brain radiotherapy. More

> Respiratory Motion added former Siemens Healthcare exec Subrata Guha as its VP of business development. The startup markets the ExSpiron monitoring system, which noninvasively tracks continuous respiratory volumes in spontaneously breathing patients. More

Biotech News

@FierceBiotech: China's WuXi raises a $290M VC fund with eyes on 'cross-border' biotech bets. Article | Follow @FierceBiotech

@JohnCFierce: The 'big' model doesn't work in drug R&D, unless you're doing a big, focused PhIII program. . Source drugs. Focus. Gamble smart. | Follow @JohnCFierce

@DamianFierce: The 2015 Biotech IPO Boom, in Requiem. Watch | Follow @DamianFierce

> Kitov Pharma's combo arthritis drug clears Phase III with an FDA filing on deck. Article

> Bristol-Myers lends Opdivo to a combo with Neon's neoantigen attack on cancer. Story

> Ted Cruz's regulatory outsourcing plan for the FDA stirs controversy. Item

> What can Gilead, Biogen and Celgene teach Big Pharma about R&D? More

Pharma News

@FiercePharma: China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. FierceAsiaPharma story | Follow @FiercePharma

@EricPFierce: AstraZeneca closing Indian API plant that Swedish regulators slammed in an inspection report. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa. More from FiercePharmaMarketing | Follow @CarlyHFierce

> FDA panel dashes Merck's hopes for broader use of Zetia, Vytorin. Report

> FDA avoids another free-speech ruling by cutting a deal with Pacira. Article

> Sanofi plots $12.5 billion Merial tradeoff with Boehringer, gaining consumer unit in the bargain. More

Pharma Manufacturing News

> AstraZeneca adding $113M packaging, warehouse facility in U.K. Report

> Sun Pharma shedding Ohio plant with sale to Nostrum Laboratories. Item

> Capsugel gets more manufacturing expertise with two-company deal. More

> Mylan wants some payback for plants it bought from Strides cited by FDA. Story

> Sweden says AstraZeneca used questionable asthma drug API from Indian plant. Article

Drug Delivery News

> Heat-enabled chemotherapy showing promise in studies. More

> More surgeons opt for spinal anesthesia in infants. Item

> Three-drug nanoparticle cuts back resistance in metastatic melanoma. Report

> Matinas' cochleate drug delivery candidate gets FDA's infectious disease product boost. Story

> Bind advances one arm of its lung cancer nanoparticle candidate, ditches another. Article

Pharma Asia News

> Fosun Group attempts to explain as high-profile chief detained by China authorities. Report

> China connection aids $280M in new funding for Pharmaron. Item

> China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. Story

> As trade pacts sprout in Asia, medical device firms need to take note. Article

> Reckitt Benckiser ordered by Australian court to pull ibuprofen painkillers. More